← Niagen Bioscience, Inc. NAGE
Market Price
$3.02
Market Cap
$243.71M
P/E Ratio
15.12
Revenue (FY 2025)
↑29.9% YoY
$129.42M
3-Yr CAGR: 21.6%
Net Income
↑103.3% YoY
$17.38M
Net Margin: 13.4%
Free Cash Flow
↑10.6% YoY
$13.21M
FCF Yield: 5.42%
EPS (Diluted)
↑81.8% YoY
$0.20
Basic: $0.22
Return on Equity
Efficiency
22.7%
ROA: 18.0%
📊 Multi-Year Historical Performance & Trends
Financial Performance History
Revenue, Net Income & Free Cash Flow
Margins Trend (%)
Gross, Operating & Net Margins
Balance Sheet Strength
Cash, Debt & Equity
Cash Flow Generation
Operating Cash Flow vs CapEx vs FCF
📈 Year-over-Year (YoY) Growth History (NAGE)
All monetary values in millions ($M)| Fiscal Year | Revenue | Revenue YoY | Gross Profit | Net Income | Net Inc YoY | Diluted EPS | EPS YoY | Op. Cash Flow | Free Cash Flow | FCF YoY |
|---|---|---|---|---|---|---|---|---|---|---|
| FY 2016 | $26.8M | — | $11.9M | $-2.9M | — | $-0.03 | — | $-2.9M | $-4.4M | — |
| FY 2017 | $21.2M | -20.9% | $10.5M | $-11.4M | -288.6% | $-0.26 | -766.7% | $-9.8M | $-11.0M | -147.0% |
| FY 2018 | $31.6M | +48.8% | $16.1M | $-33.3M | -192.8% | $-0.61 | -134.6% | $-20.9M | $-22.2M | -102.6% |
| FY 2019 | $46.3M | +46.7% | $25.8M | $-32.1M | +3.5% | $-0.56 | +8.2% | $-20.4M | $-21.2M | +4.7% |
| FY 2020 | $59.3M | +28.0% | $35.3M | $-19.9M | +38.0% | $-0.33 | +41.1% | $-10.6M | $-10.6M | +49.7% |
| FY 2021 | $67.4M | +13.8% | $41.5M | $-27.1M | -36.2% | $-0.40 | -21.2% | $-24.2M | $-24.2M | -126.9% |
| FY 2022 | $72.0M | +6.8% | $42.8M | $-16.5M | +39.0% | $-0.24 | +40.0% | $-15.1M | $-15.4M | +36.1% |
| FY 2023 | $83.6M | +16.0% | $50.8M | $-4.9M | +70.1% | $-0.07 | +70.8% | $7.1M | $7.0M | +145.2% |
| FY 2024 | $99.6M | +19.2% | $61.6M | $8.6M | +273.1% | $0.11 | +257.1% | $12.1M | $11.9M | +71.4% |
| FY 2025 | $129.4M | +29.9% | $83.2M | $17.4M | +103.3% | $0.20 | +81.8% | $13.5M | $13.2M | +10.6% |
Valuation
Market Price
$3.02
Market Cap
$243.71M
Enterprise Value
N/A
P/E Ratio
15.12
P/B Ratio
3.15
FCF Yield
5.42%
Dividend Yield
N/A
Shares Outstanding
Profitability & Margins
Gross Margin
64.28%
Operating Margin
12.58%
Net Margin
13.43%
Return on Equity (ROE)
22.71%
Return on Assets (ROA)
17.96%
Asset Turnover
1.34x
Revenue 3-Yr CAGR
21.56%
Financial Health & Liquidity
Current Ratio
12.54
Cash Ratio
5.76
Debt / Equity
N/A
Debt / Assets
N/A
Cash & Equivalents
$44.50M
Total Debt
N/A
Book Value / Share
$0.96
Cash Flow Efficiency
Operating Cash Flow
$13.50M
Capital Expenditures (CapEx)
$292.00K
Free Cash Flow
$13.21M
OCF / Revenue
10.43%
FCF / Revenue
10.21%
FCF 3-Yr CAGR
N/A
Per Share Metrics
EPS (Diluted)
$0.20
EPS (Basic)
$0.22
Dividends / Share
N/A
Book Value / Share
$0.96
EPS YoY Growth
81.82%
Balance Sheet (FY 2025)
Total Assets
$96.81M
Total Liabilities
$7.72M
Stockholders' Equity
$76.53M
Current Assets
$96.81M
Current Liabilities
$7.72M